Correction: Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial (PLoS ONE (2017) 12:2 (e0169255) DOI: 10.1371/journal.pone.0169255);Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Konde, Mandy Kader ^a,b   Baker, Darren P ^c   Traore, Fode Amara ^d   Sow, Mamadou Saliou ^d   Camara, Alioune ^b   Barry, Alpha Amadou ^b   Mara, Doussou ^b   Barry, Abdoulaye ^b   Cone, Moussa ^b   Kaba, Ibrahima ^d   Richard, Amento Ablam ^b   Beavogui, Abdoul Habib ^b   Günther, Stephan ^e   Pintilie, Melania ^f   Fish, Eleanor N ^g,h   Duraffour, Sophie ^e   Bore, Joseph Akoi ^e   Koundouno, Fara Raymond ^e   Hinzmann, Julia ^e,i   Mertens, Marc ^e,j   Vitoriano, Inês ^e,k   Logue, Christopher H ^e,k   Boettcher, Jan Peter ^e,i   Pallash, Elisa ^e   Sachse, Andreas ^e,i   Bah, Amadou ^e,l   Cabeza Cabrerizo, Mar ^e   Nitzsche, Katja ^e   Kuisma, Eeva ^e,k   Michel, Janine ^e,i   Holm, Tobias ^e   Zekeng, Elsa G ^e,m   García Dorival, Isabel ^e,m   more..

^a Sustainable Health Foundation (FOSAD)   (Guinea)

^b Center of Excellence for Training on Research and Priority Diseases (CEFORPAG)   (Guinea)

^c GENZYME CORPORATION   (United States)

^d Donka National Hospital   (Guinea)

^e BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ ROBERT KOCH INSTITUTE   (Germany)

^j FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^k PUBLIC HEALTH ENGLAND   (United Kingdom)

^l SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^m UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; ANTIVIRUS AGENT;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EBOLA HEMORRHAGIC FEVER; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; SURVIVAL; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; YOUNG ADULT; ADOLESCENT; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; INTERFERON BETA-1A; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85013391410     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175930     Document Type: Erratum

References (19)

1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849-862. doi: 10.1016/S0140-6736(10)60667-8 PMID: 21084112
2. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA et al. Clinical presentation of patients with ebola virus disease in Conakry, Guinea. N Engl J Med. 2015; 372: 40-47. doi: 10.1056/NEJMoa1411249 PMID: 25372658
3. Martinez MJ, Salim AM, Hurtado JC, Kilgore PE. Ebola virus infection: overview and update on prevention and treatment. Infect Dis Ther. 2015; 4: 365-90. doi: 10.1007/s40121-015-0079-5 PMID: 26363787
4. WHO: apps.who.int/ebola-situation-reports
5. Faye O, Andronico A, Faye O, Salje H, Boëlle PY, Magassouba N et al. Use of viremia to evalaute the baseline case fatality ratio of ebola virus disease and inform treatment studies: a retrospective cohort study. PLOS Med. 2015; 12: e1001908. doi: 10.1371/journal.pmed.1001908 PMID: 26625118
6. Wang BX, Fish EN. The yin and yang of viruses and interferons. Trends Immunol. 2012; 33: 190-197. doi: 10.1016/j.it.2012.01.004 PMID: 22321608
7. Cardenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martínez-Sobrido L et al. J Virol. 2006; 80: 5168-5178. doi: 10.1128/JVI.02199-05 PMID: 16698997
8. Yen B, Mulder LC, Martinez O, Basler CF. Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J Virol. 2014; 88: 12500-12510. doi: 10.1128/JVI.02163-14 PMID: 25142601
9. Audet J, Kobinger GP. Immune evasion in ebolavirus infections. Viral Immunol. 2015; 28: 1-9.
10. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A et al. Interferon-ß therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis. 2013; 208: 310-318. doi: 10.1093/infdis/jis921 PMID: 23255566
11. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bra M, Jaax NK et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental ebola virus infections. J Infect Dis. 1999; 179: S224-234. doi: 10.1086/514310 PMID: 9988188
12. Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J et al. mAbs and Ad-vectored IFN-α therapy rescue ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Science Transl Med. 2013; 5: 1-10.
13. Richardson JS, Wong G, Pillet S, Schindle S, Ennis J, Turner J et al. Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents. J Bioterr Biodef. 2011; S1:007.
14. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan ebola virus. J Infect Dis. 2007; 196: S357-S363. doi: 10.1086/520611 PMID: 17940971
15. McCarthy SD, Majchrzak-Kita B, Racine T, Kozlowski HN, Baker DP, Hoenen T et al. A rapid screening assay identifies monotherapy with interferon-ß and combination therapies with nucleoside analogs as effective inhibitors of ebola virus. PLOS NTD 2016; 10: e0004364.
16. WHO. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line worker. http://www.who.int/csr/resources/publications/clinical-management-patients/en/
17. Hochberg H. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-803.
18. Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, S. Baize S et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLOS Med. 2016; 10:1001967.
19. De la Vega M-A, Stein D, Kobinger GP. Ebolavirus evolution: past and present. PLOS Pathogens 2015; 11: e1005221. doi: 10.1371/journal.ppat.1005221 PMID: 26562671